Janus Henderson Global Life Sciences T (JAGLX)

Fund Assets	4.28B
Expense Ratio	0.92%
Min. Investment	$2,500
Turnover	35.00%
Dividend (ttm)	3.87
Dividend Yield	5.53%
Dividend Growth	33.40%
Payout Frequency	Annual
Ex-Dividend Date	Dec 6, 2024

Previous Close	69.47
YTD Return	2.96%
1-Year Return	-5.97%
5-Year Return	44.83%
52-Week Low	61.32
52-Week High	81.45
Beta (5Y)	0.63
Holdings	109
Inception Date	Dec 31, 1998

About JAGLX

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

• Fund Family: Janus Henderson
• Category: Health
• Stock Exchange: NASDAQ
• Ticker Symbol: JAGLX
• Share Class: Class T
• Index: MSCI World/Health Care NR

Performance

JAGLX had a total return of -5.97% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.95%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
JFNNX	Class N	0.68%
JFNIX	Class I	0.77%
JNGLX	Class D	0.80%
JFNAX	Class A	0.98%

Top 10 Holdings

38.16% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	8.87%
UnitedHealth Group Incorporated	UNH	4.51%
AstraZeneca PLC	AZNCF	4.15%
Boston Scientific Corporation	BSX	3.44%
Abbott Laboratories	ABT	3.42%
Johnson & Johnson	JNJ	3.15%
Sanofi	SNYNF	2.89%
Novartis AG	NVS	2.64%
Amgen Inc.	AMGN	2.58%
AbbVie Inc.	ABBV	2.51%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 6, 2024	$3.86839	Dec 6, 2024
Dec 7, 2023	$2.89991	Dec 7, 2023
Dec 20, 2022	$0.09366	Dec 20, 2022
Dec 20, 2021	$6.73381	Dec 20, 2021
Dec 17, 2020	$5.50316	Dec 17, 2020
Dec 17, 2019	$3.76557	Dec 17, 2019